Hypolipaemic effect of guanfacine: Two years' follow-upHAUGER-KLEVENE, J. H.Drugs under experimental and clinical research. 1984, Vol 10, Num 2, pp 133-140, issn 0378-6501Article

In vitro studies on the distribution of probucol among human plasma lipoproteinsSAIK URIEN; RIANT, P; ALBENGRES, E et al.Molecular pharmacology. 1984, Vol 26, Num 2, pp 322-327, issn 0026-895XArticle

Plantes à saponine et régulation des dyslipémies = Saponine inplants and dyslipemiasBERGERET, C.Cahiers de biothérapie (Paris). 1984, Num 81, pp 55-57, issn 0301-1178Article

Cardiac and hepatic acyl-CoA and acylcarnitine hydrolase activities in clofibrate-fed rabbitsMOORE, K. H; SOLOMON, F. J.Comparative biochemistry and physiology. C. Comparative pharmacology. 1985, Vol 80, Num 2, pp 355-359, issn 0306-4492Article

Disposition of etofibrate, clofibric and nicotinic acid esters, and their products in dogsGARRETT, E. R; ALTMAYER, P.Journal of pharmaceutical sciences. 1985, Vol 74, Num 3, pp 295-299, issn 0022-3549Article

Hépatotoxicité des hypolipémiantsLARREY, Dominique.Hépato-gastro (Montrouge). 2004, Vol 11, Num 6, pp 407-413, issn 1253-7020, 7 p.Article

PANORAMA ACTUEL DES MEDICAMENTS HYPOLIPEMIANTSHELLER F; HARVENGT C.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 209-219; BIBL. 3 P.Article

The Ebbs and Flows in the Development of Cholesterol-Lowering Drugs: Prospects for the FutureHAJHOSSEINY, R; SABIR, I; KHAVANDI, K et al.Clinical pharmacology and therapeutics. 2014, Vol 96, Num 1, pp 64-73, issn 0009-9236, 10 p.Article

Rapid determination of clofibric acid in human plasma by high-performance liquid chromatographyPAILLET, M; DOUCET, D; MERDJEAN, H et al.Journal of chromatography. 1986, Vol 375, Num 1, pp 179-183, issn 0021-9673Article

Proceedings/Fenofibrate, a third-generation fibric acid derivative, symposium, Dallas TX, November 15, 1986BROWN, W. V.The American journal of medicine. 1987, Vol 83, Num 5, issn 0002-9343, 89 p., BConference Proceedings

Distinction entre patients bons synthétiseurs et bons absorbeurs pour optimiser le traitement hypocholestérolémiant : Thérapeutique = Distinction between good synthesizer and good absorber patients to optimize cholesterol-lowering therapyRADERMECKER, Régis P; SCHEEN, André J.Revue médicale suisse. 2006, Vol 2, Num 76, pp 1910-1915, issn 1660-9379, 6 p.Article

À la découverte de l'ézétimibe = EzetimibeWATKINS, C.La Lettre du cardiologue. 2004, Num 378, pp 44-45, issn 0761-5035, 2 p.Article

Lescol, vastin : Generic name : FluvastatinMALLARKEY, G.Current therapeutics. 1996, Vol 37, Num 4, pp 81-83, issn 0311-905XArticle

Current approaches to drug therapy for the hypercholesterolemic patientWITZTUM, J. L.Circulation (New York, N.Y.). 1989, Vol 80, Num 5, pp 1101-1114, issn 0009-7322, 14 p.Article

Suitability of laboratory animals for screening anti-hyperlipidemic agentsNEELA RAJWADE; DESAI, N. K; JOSHI, V. G et al.Journal of Postgraduate Medicine (Bombay). 1989, Vol 35, Num 3, pp 162-170, issn 0022-3859, 9 p.Article

The effects of hypolipidemic agents derived from procetofenic acid on the activity of superoxide dismutase and glutathione peroxidase and on malonyl dialdehyde production of rat liverCIRIOLO, M. R; ROSSI, L; MAVELLI, I et al.Arzneimittel-Forschung. 1984, Vol 34, Num 4, pp 465-467, issn 0004-4172Article

Drug treatment of hyperlipidemiaJONES, P; GOTTO, A. M. JR.Modern concepts of cardiovascular disease. 1984, Vol 53, Num 10, pp 53-58, issn 0026-7600Serial Issue

Manifestations rhumatologiques de certains médicaments : quinolone, hypolipémiants, quinidine = Rheumatologic manifestations of some drugs: quinolone, antilipemic agents, quinidineBOURGEOIS, P; VIGNERON, A.-M; KOEGER, A.-C et al.L' Actualité rhumatologique. 1990, Vol 27, pp 58-67, issn 0065-1818, 10 p.Article

A REAPPRAISAL OF THE MECHANISMS OF HYPOCHOLESTEROLEMIC ACTION OF THERAPEUTIC AGENTSSODHI HS; KUDCHODKAR BJ; CLIFFORD C et al.1978; ADV. EXPER. MED. BIOL.; USA; DA. 1978; VOL. 109; PP. 331-345; BIBL. 33 REF.Conference Paper

LES MEDICAMENTS HYPOLIPIDEMIANTSBONTE JP; BERTHELOT P.1980; BULL. SOC. PHARM. LILLE; ISSN 0366-3507; FRA; DA. 1980; VOL. 36; NO 3-4; PP. 243-262; BIBL. 2 P.Article

Role of phytosterols in lipid-lowering: current perspectivesGUPTA, A. K; SAVOPOULOS, C. G; AHUJA, J et al.QJM (Oxford. 1994. Print). 2011, Vol 104, Num 4, pp 301-308, issn 1460-2725, 8 p.Article

Statins in dermatologyJOWKAR, Farideh; MOHAMMAD REZA NAMAZI.International journal of dermatology. 2010, Vol 49, Num 11, pp 1235-1243, issn 0011-9059, 9 p.Article

The Acute (Cerebro)Vascular Effects of StatinsPRINZ, Vincent; ENDRES, Matthias.Anesthesia and analgesia. 2009, Vol 109, Num 2, pp 572-584, issn 0003-2999, 13 p.Article

A peri-operative statin update for non-cardiac surgery. Part II: Statin therapy for vascular surgery and peri-operative statin trial designBICCARD, B. M.Anaesthesia. 2008, Vol 63, Num 2, pp 162-171, issn 0003-2409, 10 p.Article

Statins down underMANT, Andrea; LOWINGER, Jocelyn; HALL, Wayne et al.British journal of clinical pharmacology. 2007, Vol 63, Num 1, pp 125-127, issn 0306-5251, 3 p.Article